Bolt Biotherapeutics (BOLT) Long-Term Investments (2021 - 2026)
Bolt Biotherapeutics (BOLT) posted Long-Term Investments of $1.0 million for Q1 2026, down 76.5% sequentially from $4.3 million in Q4 2025, and down 94.67% YoY from $19.1 million in Q1 2025.
Bolt Biotherapeutics (BOLT) Long-Term Investments (2021 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Long-Term Investments for 6 years, with the latest figure at $1.0 million in Q1 2026.
- Quarterly Long-Term Investments fell 94.67% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 94.67% YoY) and the FY2025 annual result came in at $4.3 million, down 81.04% from the prior year.
- Long-Term Investments slipped to $1.0 million in Q1 2026 per BOLT's latest filing, from $4.3 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $54.3 million in Q1 2022 and troughed at $1.0 million in Q1 2026.
- A 5-year average of $25.4 million and a median of $23.8 million in 2024 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2022 and 2026: Long-Term Investments jumped 49.89% in 2022, then slumped 94.67% in 2026.
- Over 5 years, Long-Term Investments stood at $23.9 million in 2022, then advanced by 10.32% to $26.4 million in 2023, then fell by 13.38% to $22.9 million in 2024, then tumbled by 81.04% to $4.3 million in 2025, then plunged by 76.5% to $1.0 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $1.0 million, $4.3 million, and $6.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Bolt Biotherapeutics | 6.10 Mn | 6.10 Mn | - | 509,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 509,000.00 |
| Mar 31, 2026 | 1.02 Mn |
| Dec 31, 2025 | 4.34 Mn |
| Sep 30, 2025 | 6.91 Mn |
| Jun 30, 2025 | 13.73 Mn |
| Mar 31, 2025 | 19.12 Mn |
| Dec 31, 2024 | 22.88 Mn |
| Sep 30, 2024 | 30.60 Mn |
| Jun 30, 2024 | 23.83 Mn |
| Mar 31, 2024 | 21.46 Mn |
| Dec 31, 2023 | 26.41 Mn |
| Sep 30, 2023 | 21.64 Mn |
| Jun 30, 2023 | 31.22 Mn |
| Mar 31, 2023 | 44.59 Mn |
| Dec 31, 2022 | 23.94 Mn |
| Sep 30, 2022 | 38.43 Mn |
| Jun 30, 2022 | 47.28 Mn |
| Mar 31, 2022 | 54.31 Mn |
| Dec 31, 2021 | 85.35 Mn |
| Sep 30, 2021 | 77.64 Mn |